Rationale and Design of a Multi-National Study of Physicians' Opinions, Attitudes, and Practices Regarding Influenza Vaccination in Patients with Cardiovascular Diseases: A Mixed Methods Designs. The FLUence Project.


Journal

Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391

Informations de publication

Date de publication:
2024
Historique:
received: 05 07 2024
accepted: 20 09 2024
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

Infections, particularly those involving the respiratory tract, are associated with an increased incidence of cardiovascular events, both de novo and as exacerbations of pre-existing cardiovascular diseases. Influenza vaccination has consistently been shown to reduce the incidence of cardiovascular events. Nonetheless, vaccination rates among adults remain suboptimal, both in the general population and among high-risk individuals. Multiple barriers hinder achieving adequate vaccination rates, with physicians' beliefs and attitudes towards these interventions being crucial. The FLUence project was developed within the framework of the World Heart Federation's Emerging Leaders program, to address this issue. This project has two phases: a global quantitative survey to assess the perceptions, opinions, and attitudes and challenges of physicians worldwide regarding the safety and efficacy of the influenza vaccination use, and a qualitative survey to further investigate the barriers and facilitators of recommending and using this vaccination. The quantitative survey was created and disseminated in five languages (English, Spanish, French, Italian, and Portuguese) to physicians of all specialties who care for adults, with a particular focus on patients with cardiovascular disease. The survey included eight domains with a total of 36 questions with closed options; a Likert scale with five possible answers was used to gauge participants' opinions. To gain deeper insights into the complexities behind the low vaccination rates in adults, the second part of the project comprises a qualitative survey, conducted in the two lower-middle- and upper-middle-income countries: India and Argentina, respectively. These countries were selected because patients with cardiovascular diseases have access to free influenza vaccination in Argentina, whereas patients must pay for the vaccine out of pocket in India. Thus, the FLUence study will provide valuable information to better understand the perceptions and barriers to improving influenza vaccination rates from the perspective of physicians. It is imperative to actively engage all healthcare providers to improve influenza vaccination rates.

Identifiants

pubmed: 39431152
doi: 10.5334/gh.1358
pmc: PMC11488190
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

78

Informations de copyright

Copyright: © 2024 The Author(s).

Déclaration de conflit d'intérêts

SGZ has conducted academic activities with Bayer, Sanofi Pasteur, Seqirus, and GlaxoSmith Kline; no external financial support has been related to this project. The other authors have nothing to declare.

Auteurs

Sebastián Garcia-Zamora (S)

Department of Research Methodology and Evidence-Based Medicine, Faculty of Medicine, National University of Rosario (UNR), Argentina.
Cardiology Department, Delta Clinic, Rosario, Argentina.
Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.

Angela S Koh (AS)

Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.
Department of Cardiology, National Heart Centre Singapore, 5 Hospital Drive, 169609, Singapore.
Duke-NUS Medical School, 8 College Road, 169857, Singapore.

Svetlana Stoica (S)

Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.
Institute for Cardiovascular Diseases Timisoara, Romania.
'Victor Babes' University of Medicine and Pharmacy Timisoara, Romania.

Nariman Sepehrvand (N)

Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.
Canadian VIGOUR Centre, and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Harish Ranjani (H)

Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.
Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai & Bengaluru, India.

Salisu Ishaku (S)

Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.
Equity in Health and Research Initiative Nigeria AND Julius Global Health, University Medical Center, Utrecht, the Netherlands.

Naomi Herz (N)

Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.
British Heart Foundation, United Kingdom.

Vanessa Kandoole-Kabwere (V)

Emerging Leaders Programme, Cohort 2022, World Heart Federation, Switzerland.
Malawi Liverpool Wellcome Trust, United Kingdom.

Pablo Perel (P)

Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
World Heart Federation, Geneva, Switzerland.

Amitava Banerjee (A)

World Heart Federation, Geneva, Switzerland.
Department of Cardiology, Barts Health NHS Trust, London, United Kingdom.
Institute of Health Informatics, University College London, London, United Kingdom.

Charlotte Warren-Gash (C)

Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.

Sean Taylor (S)

World Heart Federation, Geneva, Switzerland.

Daniel José Piñeiro (DJ)

Department of Medicine, University of Buenos Aires, Buenos Aires, Argentina.

María Inés Sosa-Liprandi (MI)

Cardiology Department, Sanatorio Güemes, Ciudad Autónoma de Buenos Aires, Argentina.

Álvaro Sosa-Liprandi (Á)

Cardiology Department, Sanatorio Güemes, Ciudad Autónoma de Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH